CRM1

KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia.

KPT185 is a selective CRM1 inhibitor. KPT-185 significantly inhibits leukemia cell proliferation with IC50 ranging from 100 nM to 500 nM, and induces cell-cycle arrest and apoptosis of AML cell lines and primary AML blasts.

Piperlongumine selectively kills cancer cells regardless of p53 status without harming normal cells. It binds to and inihbits proteins known to regulate oxidative stress, in particular, Glutathione S-transferase pi 1 (GSTP1).

KPT276, analog of KPT-185, is a selective inhibitor of nuclear export (SINE) and CRM1.

Eltanexor, also known as KPT-8602, is a second-generation exportin-1 inhibitor.

CBS9106 (SL-801) is a reversible oral CRM1 inhibitor with CRM1 degrading and antitumor activities.

Leptomycin B (CI 940; LMB) is a potent inhibitor of the nuclear export of proteins. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue. Leptomycin B is a potent antifungal antibiotic blocking the eukaryotic cell cycle.

Eltanexor Z-isomer (KPT-8602 Z-isomer) is the less active isomer of KPT-8602. KPT-8602 is a potent CRM1 inhibitor.

Selinexor trans-isomer is a trans-isomer of Selinexor or KPT-330, which is a CRM1-selective inhibitor of nuclear export. It inhibits protein trafficking from the nucleus and induces cell cycle arrest and apoptosis in mesothelioma cells.

CRM1 Degrader 1 is a targeted agent that selectively degrades chromosome region maintenance 1 (CRM1), a nuclear exporter critical for the transport of various tumor suppressor proteins. By inducing apoptosis in gastric carcinoma cells, CRM1 Degrader 1 demonstrates significant anti-proliferative effects, making it a valuable tool for cancer research. This compound is primarily used to explore therapeutic strategies aimed at regulating CRM1-related pathways in cancer biology.